Latest Breaking News On - Denovo biopharma - Page 14 : vimarsana.com

Press release content from Accesswire. The AP news staff was not involved in its creation. Aytu BioPharma Adds Late-Stage Pediatric Onset Rare Disease Asset to Development Pipeline from Rumpus Therapeutics April 12, 2021 GMT Aytu gains global license to pivotal study-ready protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) in rare disease indicationsProgram initially targeting vascular Ehlers-Danlos Syndrome (vEDS), a rare inherited connective tissue . Aytu gains global license to pivotal study-ready protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) in rare disease indicationsProgram initially targeting vascular Ehlers-Danlos Syndrome (vEDS), a rare inherited connective tissue . Aytu gains global license to pivotal study-ready protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) in rare disease indications

United statesHal dietzAytu biopharmaChristopher brookeJosh disbrowKatie wrightLara bloomNathaniel massariJosephine grimaSarah mccabeNate massariJohns hopkins universityMarfan foundationStern investor relations incHealth life sciencesWharton school